

# Jamie T Griffin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10675412/publications.pdf>

Version: 2024-02-01

42  
papers

4,152  
citations

147801

31  
h-index

289244

40  
g-index

42  
all docs

42  
docs citations

42  
times ranked

4917  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hitting Hotspots: Spatial Targeting of Malaria for Control and Elimination. PLoS Medicine, 2012, 9, e1001165.	8.4	460
2	Reducing Plasmodium falciparum Malaria Transmission in Africa: A Model-Based Evaluation of Intervention Strategies. PLoS Medicine, 2010, 7, e1000324.	8.4	451
3	Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infectious Diseases, The, 2015, 15, 1450-1458.	9.1	262
4	Age-Patterns of Malaria Vary with Severity, Transmission Intensity and Seasonality in Sub-Saharan Africa: A Systematic Review and Pooled Analysis. PLoS ONE, 2010, 5, e8988.	2.5	228
5	The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa. ELife, 2016, 5, .	6.0	194
6	Modelling the impact of vector control interventions on Anopheles gambiae population dynamics. Parasites and Vectors, 2011, 4, 153.	2.5	177
7	Mosquito feeding behavior and how it influences residual malaria transmission across Africa. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15086-15095.	7.1	172
8	Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa. Nature Communications, 2014, 5, 3136.	12.8	169
9	The Relationship between RTS,S Vaccine-Induced Antibodies, CD4+ T Cell Responses and Protection against Plasmodium falciparum Infection. PLoS ONE, 2013, 8, e61395.	2.5	163
10	Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet, The, 2016, 387, 367-375.	13.7	154
11	Malaria morbidity and mortality in Ebola-affected countries caused by decreased health-care capacity, and the potential effect of mitigation strategies: a modelling analysis. Lancet Infectious Diseases, The, 2015, 15, 825-832.	9.1	141
12	Dynamics of the Antibody Response to Plasmodium falciparum Infection in African Children. Journal of Infectious Diseases, 2014, 210, 1115-1122.	4.0	124
13	The Potential Contribution of Mass Treatment to the Control of Plasmodium falciparum Malaria. PLoS ONE, 2011, 6, e20179.	2.5	121
14	Estimating the most efficient allocation of interventions to achieve reductions in Plasmodium falciparum malaria burden and transmission in Africa: a modelling study. The Lancet Global Health, 2016, 4, e474-e484.	6.3	107
15	Probability of Transmission of Malaria from Mosquito to Human Is Regulated by Mosquito Parasite Density in Naïve and Vaccinated Hosts. PLoS Pathogens, 2017, 13, e1006108.	4.7	104
16	Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study. Lancet Infectious Diseases, The, 2016, 16, 465-472.	9.1	102
17	Gradual acquisition of immunity to severe malaria with increasing exposure. Proceedings of the Royal Society B: Biological Sciences, 2015, 282, 20142657.	2.6	91
18	Systematic review of indoor residual spray efficacy and effectiveness against Plasmodium falciparum in Africa. Nature Communications, 2018, 9, 4982.	12.8	90

#	ARTICLE	IF	CITATIONS
19	Loss of Population Levels of Immunity to Malaria as a Result of Exposure-Reducing Interventions: Consequences for Interpretation of Disease Trends. <i>PLoS ONE</i> , 2009, 4, e4383.	2.5	86
20	Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. <i>Nature Communications</i> , 2014, 5, 5606.	12.8	85
21	A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. <i>BMC Medicine</i> , 2014, 12, 117.	5.5	73
22	Defining the relationship between infection prevalence and clinical incidence of <i>Plasmodium falciparum</i> malaria. <i>Nature Communications</i> , 2015, 6, 8170.	12.8	67
23	The impact of hotspot-targeted interventions on malaria transmission: study protocol for a cluster-randomized controlled trial. <i>Trials</i> , 2013, 14, 36.	1.6	55
24	Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials. <i>Malaria Journal</i> , 2010, 9, 82.	2.3	52
25	Serology describes a profile of declining malaria transmission in Farafenni, The Gambia. <i>Malaria Journal</i> , 2015, 14, 416.	2.3	49
26	Assessing the potential impact of artemisinin and partner drug resistance in sub-Saharan Africa. <i>Malaria Journal</i> , 2016, 15, 10.	2.3	48
27	A model of parity-dependent immunity to placental malaria. <i>Nature Communications</i> , 2013, 4, 1609.	12.8	46
28	Key traveller groups of relevance to spatial malaria transmission: a survey of movement patterns in four sub-Saharan African countries. <i>Malaria Journal</i> , 2016, 15, 200.	2.3	43
29	Modelling the cost-effectiveness of introducing the RTS,S malaria vaccine relative to scaling up other malaria interventions in sub-Saharan Africa. <i>BMJ Global Health</i> , 2017, 2, e000090.	4.7	39
30	Protective Efficacy of Intermittent Preventive Treatment of Malaria in Infants (IPTi) Using Sulfadoxine-Pyrimethamine and Parasite Resistance. <i>PLoS ONE</i> , 2010, 5, e12618.	2.5	37
31	Seasonality in malaria transmission: implications for case-management with long-acting artemisinin combination therapy in sub-Saharan Africa. <i>Malaria Journal</i> , 2015, 14, 321.	2.3	34
32	Joint estimation of the basic reproduction number and generation time parameters for infectious disease outbreaks. <i>Biostatistics</i> , 2011, 12, 303-312.	1.5	26
33	The Interaction between Seasonality and Pulsed Interventions against Malaria in Their Effects on the Reproduction Number. <i>PLoS Computational Biology</i> , 2015, 11, e1004057.	3.2	23
34	The US President's Malaria Initiative, <i>Plasmodium falciparum</i> transmission and mortality: A modelling study. <i>PLoS Medicine</i> , 2017, 14, e1002448.	8.4	23
35	Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2011, 278, 1298-1305.	2.6	15
36	Modelling the benefits of long-acting or transmission-blocking drugs for reducing <i>Plasmodium falciparum</i> transmission by case management or by mass treatment. <i>Malaria Journal</i> , 2017, 16, 341.	2.3	11

#	ARTICLE	IF	CITATIONS
37	Is a reproduction number of one a threshold for Plasmodium falciparum malaria elimination?. Malaria Journal, 2016, 15, 389.	2.3	10
38	Risk factors for UK Plasmodium falciparum cases. Malaria Journal, 2014, 13, 298.	2.3	9
39	Modelling population-level impact to inform target product profiles for childhood malaria vaccines. BMC Medicine, 2018, 16, 109.	5.5	8
40	The design and statistical power of treatment re-infection studies of the association between pre-erythrocytic immunity and infection with Plasmodium falciparum. Malaria Journal, 2013, 12, 278.	2.3	3
41	Predictive Malaria Epidemiology, Models of Malaria Control Interventions and Elimination. , 2018, , 1-7.		0
42	Predictive Malaria Epidemiology, Models of Malaria Transmission and Elimination. , 2018, , 1-7.		0